0001439222-20-000008.txt : 20200218 0001439222-20-000008.hdr.sgml : 20200218 20200218160533 ACCESSION NUMBER: 0001439222-20-000008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200213 FILED AS OF DATE: 20200218 DATE AS OF CHANGE: 20200218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bowden Christopher CENTRAL INDEX KEY: 0001608601 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36014 FILM NUMBER: 20625279 MAIL ADDRESS: STREET 1: 38 SIDNEY STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-8600 MAIL ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20080703 4 1 wf-form4_158205991627413.xml FORM 4 X0306 4 2020-02-13 0 0001439222 AGIOS PHARMACEUTICALS, INC. AGIO 0001608601 Bowden Christopher C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Medical Officer Common stock 2020-02-13 4 M 0 7100 35.16 A 8750 D Common stock 2020-02-13 4 S 0 7100 50.1566 D 1650 D Stock option (right to buy) 35.16 2020-02-13 4 M 0 7100 0 D 2024-05-30 Common stock 7100.0 19306 D This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.82. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. /s/ William Cook, as Attorney-in-fact for Christopher Bowden 2020-02-18